### Appendix Table. XDR TB patient characteristics, Italy and Germany, 2003–2006*

| Age (y), Of | Country | Radiologic cavities, thorax† | No. treatment periods‡ | Drugs received§ | Drug resistance†§ | Hospitalization, d | Smear conversion, d | Culture conversion, d | Treatment duration, mo | Outcome¶ |
|------------|---------|-----------------------------|----------------------|-----------------|-------------------|------------------|------------------|------------------|-----------------------|---------|
| 40, M Italy | Italy   | Bilateral                   | 3                    | S, R, H, E, Z; FQ, Eth, Ak, PAS, Cyc | S, R, H, E, Z; FQ, AK, Cyc | 220              | –                | –                | 73                    | Improved          |
| 61, F Italy | Italy   | Monolateral                 | 1                    | S, R, H, E, Z; FQ, Eth, Ak, PAS, Cyc | S, R, H, E, Z; FQ, AK, Cyc | 83               | –                | –                | 16                    | Died               |
| 27, F Italy | Moldova | Monolateral                 | 3                    | S, R, H, E, Z; FQ Eth AK, PAS, Cyc, Clof | S, R, H, Z; FQ, Eth, K | 406              | 300              | 300              | 10                    | Improved          |
| 46, M Italy | Italy   | Bilateral                   | 4                    | S, R, H, E, Z; FQ, PAS, Cyc | S, R, H, Z; FQ, Eth, AK, PAS | 69               | 49               | 35               | 6                     | Improved          |
| 43, F Italy | Italy   | Bilateral                   | 3                    | S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Clof, Dap, Cl, Th | S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th | 422              | –                | –                | 94                    | Died               |
| 38, F Italy | Italy   | Bilateral                   | 3                    | S, R, H, E, Z; FQ, Eth, PAS, C, Cyc | S, R, H, E, Z; FQ, AK, PAS, Cyc | 80               | –                | –                | 12                    | Died               |
| 49, F Italy | Italy   | Bilateral                   | 3                    | S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th | S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th | 625              | –                | –                | 60                    | Died               |
| 33, M Germany | Uzbekistan | Monolateral               | 2                    | S, R, H, E, Z | S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th | 120              | –                | –                | 4                     | Improved          |
| 29, M Germany | Uzbekistan | Bilateral               | 2                    | S, R, H, E, Z; Rb | S, R, H, E, Z; FQ, C | 240              | 180              | 160              | 12                    | Improved          |
| 52, M Germany | Azerbaijan | Monolateral               | >1                   | Not available | S, R, H, E, Z; FQ, AK, PAS, C, Cyc, Rb | 140              | 7                | 35               | 6                     | Improved          |
| 36, F Italy | Romania | Bilateral                   | 4                    | S, R, H, E, Z; FQ, Eth, PAS, Cyc, Rb | R, H, Z; FQ, AK, Rb | 248              | 110              | –                | 28                    | Improved          |

*XDR TB, extensively drug-resistant tuberculosis; –, not achieved. All patients were HIV seronegative.

†At time of XDR TB diagnosis.

‡Treatment periods >30 d.

§First-line drugs: S, streptomycin; R, rifampin; H, isoniazid; E, ethambutol; Z, pyrazinamide; second-line drugs: FQ, fluoroquinolone; Eth, ethionamide; AK, amikacin; PAS, para-aminosalicylic acid;
C, capreomycin; K, kanamycin; Cyc, cycloserine; other drugs: Rb, rifabutin; Clof, clofazimine; Dap, dapsone; Cl, clarithromycin; Th, thiacetazone.

¶Improved, achieved bacteriologic conversion, radiologic and clinical improvement, or both.